TP53 RB1 and PTEN alterations affect prognosis and ARPI response in metastatic hormone-sensitive prostate cancer, potential for treatment personalization based on both genomic testing and clinical ...

Zachary Klaassen hosts Andrew Hahn to discuss future directions in metastatic castration-resistant prostate cancer. Dr. Hahn highlights the "golden era" for targeting cell surface proteins through ...

Erectile Dysfunction - Read the latest Erectile Dysfunction research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

(UroToday.com) The 2025 European Association of Urology (EAU) Annual Congress held in Madrid, Spain between March 21 st and 24 th 2025, was host to a thematic session on intravesical therapy for ...

Prostatitis - Read the latest Prostatitis research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

PSMA and Beyond 2025 antibody drug development (ADC) in prostate cancer, ADC program in advance prostate cancer, PSMA expression, ...

BPH - Read the latest BPH research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

ASCO 2025 ProstACT Global, phase 3 study of 177Lu-rosptamab + standard of care versus standard of care alone, metastatic castration-resistant prostate cancer (mCRPC).

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.